

Amendments to the Claims:

Claims 1-2 (Canceled).

3. (Currently amended): ~~The classic IBDV mutant according to claim 1, A classic infectious bursal disease virus (IBDV) mutant that expresses a VP2 protein that binds with monoclonal antibody (moab) B69, wherein the VP2 protein also binds with moab 67, secreted by hybridoma cell lines HB-9437 and HB-11122, deposited at the ATCC, Rockville, USA, respectively,~~ wherein the mutant comprises one or more mutations in a classic VP2 coding region, such that the coding region comprises,

- (i) a codon for the amino acid at position 222 encoding ~~an amino acid selected from the group consisting of serine and~~ threonine, and
- (ii) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID. No. 1, SEQ ID. No. 2, SEQ ID. No. 3, SEQ ID. No. 4 and SEQ ID. No. 5 at positions 318-323.

4. (Currently amended): ~~[[A]]~~ The classic IBDV mutant according to claim 3, wherein the coding region comprises a codon for the amino acid at position 330 encoding an amino acid selected from the group consisting of arginine and serine.

5. (Currently amended): The classic IBDV mutant according to ~~claim 1,~~ claim 3, wherein the mutant comprises one or more mutations in a VP2 coding region of IBDV strain D78.

6. (Currently amended): The classic IBDV mutant according to ~~claim 1,~~ claim 3, wherein the mutant comprises a genomic segment A of ~~a classic IBDV,~~ preferably of IBDV strain D78.

7. (Currently amended): An immunogenic composition for raising antibodies in poultry against IBDV comprising a classic IBDV mutant according to ~~claim 1,~~ claim 3, together with a ~~pharmaceutical~~ pharmaceutically acceptable carrier or diluent.
8. (Previously presented): The immunogenic composition according to claim 7, wherein the classic IBDV mutant is in a live form.
9. (Currently amended): The immunogenic composition according to claim 7, ~~wherein the vaccine~~ which further comprises one or more ~~vaccine components~~ immunogens of other pathogens infectious to poultry.
10. (Currently amended): The immunogenic composition according to claim 7, ~~wherein the vaccine~~ which comprises an adjuvant.

Claims 11-19 (Canceled).

20. (New): A classic infectious bursal disease virus (IBDV) mutant that expresses a VP2 protein that binds with monoclonal antibody (moab) B69, wherein the VP2 protein also binds with moab 67, secreted by hybridoma cell lines HB-9437 and HB-11122, deposited at the ATCC, Rockville, USA, respectively, wherein the mutant comprises one or more mutations in a classic VP2 coding region, such that the coding region comprises,
- (i) a codon for the amino acid at position 222 encoding an amino acid selected from the group consisting of serine and threonine, and
 - (ii) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID. No. 2, SEQ ID. No. 3, SEQ ID. No. 4 and SEQ ID. No. 5 at

positions 318-323.

- 21. (New): A classic IBDV mutant according to claim 20, wherein the coding region comprises a codon for the amino acid at position 330 encoding an amino acid selected from the group consisting of arginine and serine.**
- 22. (New): The classic IBDV mutant according to claim 20, wherein the mutant comprises one or more mutations in a VP2 coding region of IBDV strain D78.**
- 23. (New): The classic IBDV mutant according to claim 20, wherein the mutant comprises a genomic segment A of IBDV strain D78.**
- 24. (New): An immunogenic composition for raising antibodies in poultry against IBDV comprising a classic IBDV mutant according to claim 20, together with a pharmaceutically acceptable carrier or diluent.**
- 25. (New): The immunogenic composition according to claim 24, wherein the classic IBDV mutant is in a live form.**
- 26. (New): The immunogenic composition according to claim 24, which further comprises one or more of other pathogens infectious to poultry.**
- 27. (New): The immunogenic composition according to claim 24, which comprises an adjuvant.**